<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111065">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060565</url>
  </required_header>
  <id_info>
    <org_study_id>HL V-0214</org_study_id>
    <nct_id>NCT02060565</nct_id>
  </id_info>
  <brief_title>Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease</brief_title>
  <acronym>PVNIM</acronym>
  <official_title>Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association HGE CHU Bordeaux Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association HGE CHU Bordeaux Sud</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this retrospective and prospective study is to evaluate the 20-year prognosis
      value of non-invasive methods for the diagnosis of chronic liver disease for predicting
      survival and complications of cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All consecutive patients with chronic liver disease will be followed during 20 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival  without liver complications</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival without liver transplantation</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Chronic liver disease</arm_group_label>
    <description>all patients with chronic liver disease followed using non-invasive methods</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all consecutive patients with an age over eighteen and chronic liver disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic hepatitis C

          -  chronic hepatitis B

          -  alcohol liver disease

          -  non alcoholic liver disease

        Exclusion Criteria:

          -  ascitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Vergniol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliette Foucher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faiza Chermak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wassil Merrouche</last_name>
    <role>Study Chair</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor de Lédinghen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Henri Bernard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Baptiste Hiriart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Association HGE CHU Bordeaux Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor de Lédinghen, MD, PhD</last_name>
    <phone>0033557656439</phone>
    <email>victor.deledinghen@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Vergniol</last_name>
    <phone>0033557656439</phone>
    <email>julien.vergniol@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre d'Investigation de la Fibrose hépatique Service Hépato-Gastroentérologie Hopital Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor de Lédinghen, MD, PhD</last_name>
      <phone>0033557656439</phone>
      <email>victor.deledinghen@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Vergniol, MD</last_name>
      <phone>0033557656439</phone>
      <email>julien.vergniol@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diagnosis</keyword>
  <keyword>survival</keyword>
  <keyword>non-invasive method</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>FibroScan</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
